Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire - AOL
And it's not too late to get in on the action.
www.aol.com
Rather than canalbilizing tirzepatide sales, management appears to be telling investors that retatrutide will be marketed to the more obese and metabolically challenged patients as to differeniate the product in the market. That should be interesting conversations at doctors offices.
Patient: Hey doc, I hear that there is this great new drug on the market and that I'll lose a ton of weight
Doc: Yeah, but you're not fat enough
Patient: Should I gain some weight
Doc: No, just use the less effective medication
Nine months later.....
Patient: Hey doc, I didn't lose enough, can I try that new drug?
Doc: Oh no, we have an adjunct called eloralintide that would be much better to add to the tirzepatide. Now you have to pay for two scripts.
And it's not too late to get in on the action.
www.aol.com
Rather than canalbilizing tirzepatide sales, management appears to be telling investors that retatrutide will be marketed to the more obese and metabolically challenged patients as to differeniate the product in the market. That should be interesting conversations at doctors offices.
Patient: Hey doc, I hear that there is this great new drug on the market and that I'll lose a ton of weight
Doc: Yeah, but you're not fat enough
Patient: Should I gain some weight
Doc: No, just use the less effective medication
Nine months later.....
Patient: Hey doc, I didn't lose enough, can I try that new drug?
Doc: Oh no, we have an adjunct called eloralintide that would be much better to add to the tirzepatide. Now you have to pay for two scripts.
